UTHR: Transforming into a pulmonary fibrosis leader with blockbuster pipeline and $40B+ revenue ambitions
A major strategic shift is underway, expanding from pulmonary hypertension to pulmonary fibrosis and COPD, with multiple new products and formats targeting large, underserved patient populations. Strong clinical data, robust IP, and aggressive sales force expansion support ambitions for $40—100 bil…